New Anticancer Drugs: Reliably Assessing “Value” While Addressing High Prices

Countries face challenges in paying for new drugs. High prices are driven in part by exploding drug development costs, which, in turn, are driven by essential but excessive regulation. Burdensome regulation also delays drug development, and this can translate into thousands of life-years lost. We ne...

Full description

Bibliographic Details

Published in:	Current Oncology
Main Authors:	David J. Stewart, John-Peter Bradford, Sandeep Sehdev, Tim Ramsay, Vishal Navani, Nigel S. B. Rawson, Di Maria Jiang, Joanna Gotfrit, Paul Wheatley-Price, Geoffrey Liu, Alan Kaplan, Silvana Spadafora, Shaun G. Goodman, Rebecca A. C. Auer, Gerald Batist
Format:	Article
Language:	English
Published:	MDPI AG 2024-04-01
Subjects:	drug costs drug value ICER QALY
Online Access:	https://www.mdpi.com/1718-7729/31/5/184